Evidence map›Paper›PMID 34907536›Full record

ArticleTransfusion2022

Retention of hemostatic and immunological properties of frozen plasma and COVID-19 convalescent apheresis fresh-frozen plasma produced and freeze-dried in Canada.

William P Sheffield, Varsha Bhakta, Anita Howell, Craig Jenkins, Katherine Serrano, Nathaniel Johnson, Yi-Chan J Lin, Karen Colwill, Bhavisha Rathod, Brianna Greenberg and 6 more

Abstract read
PubMed Publisher
In one paragraph

Article in Transfusion, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 7 institutions in 3 countries.

William P SheffieldCentre for Innovation, Canadian Blood Services, Edmonton, Hamilton, Ottawa, and Vancouver, Canada.ORCID 0000-0002-5870-8189
Varsha BhaktaCentre for Innovation, Canadian Blood Services, Edmonton, Hamilton, Ottawa, and Vancouver, Canada.
Anita HowellCentre for Innovation, Canadian Blood Services, Edmonton, Hamilton, Ottawa, and Vancouver, Canada.
Craig JenkinsCentre for Innovation, Canadian Blood Services, Edmonton, Hamilton, Ottawa, and Vancouver, Canada.
Katherine SerranoCentre for Innovation, Canadian Blood Services, Edmonton, Hamilton, Ottawa, and Vancouver, Canada.
Nathaniel JohnsonScientific Affairs, Terumo BCT, Lakewood, Colorado, USA.
Yi-Chan J LinDepartment of Medical Microbiology & Immunology, University of Alberta, Edmonton, Canada.
Karen ColwillLunenfeld-Tanenbaum Research Institute, Sinai Health, Toronto, Canada.
Bhavisha RathodLunenfeld-Tanenbaum Research Institute, Sinai Health, Toronto, Canada.
Brianna GreenbergDepartment of Surgery, University of Toronto, Toronto, Canada.
Anne-Claude GingrasLunenfeld-Tanenbaum Research Institute, Sinai Health, Toronto, Canada.
David H EvansDepartment of Medical Microbiology & Immunology, University of Alberta, Edmonton, Canada.
Elissa FlaumenhaftScientific Affairs, Terumo BCT, Lakewood, Colorado, USA.
Andrew BeckettHealth Services, Canadian Forces, Ottawa, Canada.ORCID 0000-0002-4943-9415
Steven J DrewsMicrobiology, Canadian Blood Services, Edmonton, Canada.ORCID 0000-0003-2519-1109
Dana V DevineCentre for Innovation, Canadian Blood Services, Edmonton, Hamilton, Ottawa, and Vancouver, Canada.ORCID 0000-0002-9059-0344
Canadian Blood Services · CAUniversity of Alberta · CALunenfeld-Tanenbaum Research Institute · CATerumo (United States) · USUniversity of British Columbia · CAUniversity of Toronto · CACanadian Armed Forces · CA

Funding

Defence Research and Development Canada (Task 54)Health CanadaThe Surgeon General's Heath Research Innovation Program
6 · The paper itself

Abstract

backgroundRandomized clinical trial data show that early plasma transfusion may save lives among trauma patients. Supplying plasma in remote environments is logistically challenging. Freeze-dried plasma (FDP) offers a possible solution. STUDY DESIGN AND

methodsA Terumo BCT plasma freeze-drying system was evaluated. We compared pooled frozen plasma (FP) units with derived Terumo BCT FDP (TFDP) units and pooled COVID-19 convalescent apheresis fresh-frozen plasma (CC-AFFP) with derived CC-TFDP units. Parameters measured were: coagulation factors (F) II; V; VII; VIII; IX; XI; XIII; fibrinogen; Proteins C (PC) and S (PS); antithrombin (AT); α

resultsMost parameters were unchanged in TFDP versus FP or differed ≤15%. Mean aPTT, PT, C3a, and pH were elevated 5.9%, 6.9%, 64%, and 0.28 units, respectively, versus FP. CC-TFDP showed no loss of SARS-CoV-2 neutralization titer versus CC-AFFP and no mean signal loss in most pools by viral protein immunoassays.

conclusionChanges in protein activities or clotting times arising from freeze-drying were <15%. Although C3a levels in TFDP were elevated, they were less than literature values for transfusable plasma. SARS-CoV-2-neutralizing antibody titers and viral protein binding levels were largely unaffected by freeze-drying. In vitro characteristics of TFDP or CC-TFDP were comparable to their originating plasma, making future clinical studies appropriate.

Indexed as

Blood Component RemovalBlood Component TransfusionCOVID-19Freeze DryingAntithrombinsCanadaCOVID-19 SerotherapyHemostaticsHumansImmunization, PassivePlasmaSARS-CoV-2Viral ProteinsAntithrombinsHemostaticsViral Proteinsblood componentfreeze-dryingplasmaplasma qualitySARS-CoV-2

Identifiers

PMID34907536
OpenAlexW4200482992

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.